Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170620 | 0.77 | — | — | |
| SCHEMBL3589332 | 0.77 | — | — | |
| SCHEMBL1855211 | 0.77 | KDM4E (0.34) | — | |
| SCHEMBL148577 | 0.67 | GABRA1 (0.39) | GABRA1GABRB2 | |
| SCHEMBL834352 | 0.67 | KDM4E (0.45) | GABRA1GABRB2PSMB5 | |
| SCHEMBL3587738 | 0.65 | KDM4E (0.33) | — | |
| SCHEMBL500314 | 0.64 | PSMB5 (0.30) | PSMB5 | |
| SCHEMBL11106776 | 0.62 | — | — | |
| SCHEMBL7118882 | 0.60 | PSMB5 (0.38) | GABRA1GABRB2PSMB5 | |
| SCHEMBL1455541 | 0.60 | PDE3B (0.32) | GABRA1GABRB2PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | claimed |
| US-20100022559-A1 | BISOXIMES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2010-01-28 | — | — | US | disclosed |
| US-7309718-B2 | Dibenzocycloheptene compound | UBE INDUSTRIES, LTD. (JP) | 2007-12-18 | — | — | US | disclosed |
| CN-1240684-C | Dibenzocycloheptene compound | UBE INDUSTRIES (JP) | 2006-02-08 | — | — | CN | disclosed |
| CN-1531528-A | Dibenzocycloheptene compound | ��˲���ʽ���� | 2004-09-22 | — | — | CN | disclosed |
| US-20040180884-A1 | Dibenzocycloheptene compound | UBE INDUSTRIES, LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1408033-A1 | DIBENZOCYCLOHEPTENE COMPOUND | Ube Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-0215435-B1 | 2-OXA-ISOCEPHEM COMPOUNDS, COMPOSITIONS CONTAINING SAME AND PROCESSES FOR PREPARING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| US-4831026-A | ANTIBIOTICS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-05-16 | — | — | US | disclosed |
| EP-0215435-A1 | 2-Oxa-isocephem compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180884-A1 | Dibenzocycloheptene compound | LTB4R2, LTA4H, LTC4S | GABRA1 663/4885GABRB2 684/4885PSMB5 825/4885 |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | GABRA1 2486/4885GABRB2 3272/4885PSMB5 362/4885 |
| US-20100022559-A1 | BISOXIMES AS FUNGICIDES | DDT, FHIT, CYP4X1 | GABRA1 908/4885GABRB2 528/4885PSMB5 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.